<DOC>
	<DOCNO>NCT01807767</DOCNO>
	<brief_summary>The objective study determine efficacy safety Everolimus conversion liver transplantation . Most large US liver center transplant patient high Model End-Stage Liver Disease ( MELD ) score . However , many sponsor liver transplant trial US include patient high MELD score make difficult extrapolate trial data patient care large liver transplant center . The great potential benefit mammalian target rapamycin ( mTOR ) inhibitor avoidance side-effects calcineurin-inhibitors , namely , renal insufficiency , diabetes hypertension . Therefore , protocol design study efficacy safety everolimus Myfortic liver transplant patient high MELD score two large center vast experience administration mTOR inhibitor .</brief_summary>
	<brief_title>Myfortic High MELD Liver Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>End Stage Liver Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Patients must give write informed consent assessment perform . 1 . MELD ≥ 25 . 2 . Recipients 1870 year age primary secondary liver transplant decease donor . 3 . Allograft function acceptable level time randomization define Aspartate Aminotransferase ( AST ) , Alanine Aminotransferase ( ALT ) , Total Bilirubin level ≤3 time Upper Limit Normal ( ULN ) , Alkaline Phosphatase ( AlkP ) level ≤ 5 time ULN . 4 . Ability willingness provide write informed consent adhere study regimen . 5 . Patients able take oral medication time randomization . Glomerular Filtration Rate ( GFR ) ≥ 30 ml/min . 1 . Patients receive 3rd transplant 2 . Fulminant hepatic failure 3 . Living donor transplant 4 . Donation Cardiac Death ( DCD ) donor split graft 5 . Active infection hemodynamic instability time transplant 6 . Renal replacement therapy clearance within 7 day prior randomization 7 . Presence thrombosis via Doppler ultrasound major hepatic artery , major hepatic vein , portal vein inferior vena cava . 8 . An episode acute rejection require antibody therapy one steroid sensitive episode acute rejection prior randomization . This include patient complete steroid treatment acute rejection within 7 day prior randomization . 9 . Spot urine protein/creatinine ratio &gt; 1g/24h time randomization 10 . Combined liver/kidney transplant 11 . Patients severe hypercholesterolemia ( &gt; 350 mg/dL ) Patients platelet count &lt; 50,000 time randomization 12 . Patients Absolute neutrophil count ( ANC ) &lt; 1,000 White Blood Count ( WBC ) &lt; 2,000 time randomization 13 . Patients hemoglobin &lt; 6g/dL 14 . Patients unable take oral medication time randomization 15 . Patients clinically significant systemic infection require active use IV antibiotic , antiviral , antifungal 16 . Patients critical care set time randomization require life support measure mechanical ventilation , dialysis , requirement vasopressor agent 17 . Known intolerance tacrolimus everolimus Myfortic .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>